These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28029415)

  • 81. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).
    Gandjour A
    Health Serv Manage Res; 2013 Nov; 26(4):103-9. PubMed ID: 25595007
    [TBL] [Abstract][Full Text] [Related]  

  • 82. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Time From Marketing Authorization to Reimbursement of Medicines in Greece After the Introduction of the Health Technology Assessment Process From July 2018 to April 2022.
    Beletsi A; Stefanou G; Kourlaba G
    Value Health Reg Issues; 2023 Jul; 36():58-65. PubMed ID: 37030032
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Role of patient and public participation in health technology assessment and coverage decisions.
    Menon D; Stafinski T
    Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):75-89. PubMed ID: 21351860
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Complex decisions about an uncomplicated therapy: reimbursement for long-term oxygen therapy in Catalonia (Spain).
    Borras JM; Granados A; Escarrabill J; de Lissovoy G
    Health Policy; 1996 Jan; 35(1):53-9. PubMed ID: 10157041
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Reimbursement programs and health technology assessment for diabetes devices and supplies: a Canadian perspective.
    Cheung RY; Mui V
    J Diabetes Sci Technol; 2015 May; 9(3):706-10. PubMed ID: 25697719
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Evidence-based decision-making and health technology assessment in South Korea.
    Park SH; Lee SM
    Value Health; 2008 Mar; 11 Suppl 1():S163-4. PubMed ID: 18387062
    [No Abstract]   [Full Text] [Related]  

  • 89. Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria.
    Iskrov G; Stefanov R
    Balkan Med J; 2016 Jan; 33(1):27-35. PubMed ID: 26966615
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Technology assessment: approach and reimbursement.
    Yaszemski MJ; Polly DW; Boden SD; Andersson GB
    Spine (Phila Pa 1976); 2007 May; 32(11 Suppl):S39-43. PubMed ID: 17495585
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Austria: history of health technology assessment during the past 20 years.
    Wild C
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():74-81. PubMed ID: 19500437
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries.
    Kaló Z; Landa K; Doležal T; Vokó Z
    Eur J Cancer Care (Engl); 2012 Jul; 21(4):442-9. PubMed ID: 22510226
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Application of HTA research on policy decision-making.
    Youngkong S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S119-26. PubMed ID: 24964709
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Reimbursement shapes market for technology.
    Wagner JL
    Hospitals; 1979 Jun; 53(11):91-4. PubMed ID: 428954
    [TBL] [Abstract][Full Text] [Related]  

  • 96. How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide.
    Diaby V; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):81-99. PubMed ID: 24328890
    [TBL] [Abstract][Full Text] [Related]  

  • 97. SOME ADDITIONAL THOUGHTS ON FORTHCOMING AMENDMENTS TO HTA IN POLAND.
    Zawada A
    Int J Technol Assess Health Care; 2017 Jan; 33(3):358-359. PubMed ID: 28927473
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study.
    Allen N; Walker SR; Liberti L; Sehgal C; Salek MS
    CMAJ Open; 2016; 4(4):E674-E678. PubMed ID: 28018881
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.
    Kovács S; Kaló Z; Daubner-Bendes R; Kolasa K; Hren R; Tesar T; Reckers-Droog V; Brouwer W; Federici C; Drummond M; Zemplényi AT
    Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):195-206. PubMed ID: 35322478
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma (2023).
    Sznurkowski JJ; Rys J; Kowalik A; Zolciak-Siwinska A; Bodnar L; Chudecka-Glaz A; Blecharz P; Zielinska A; Marszalek A; Bidzinski M; Sawicki W
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.